Versanis Bio is a privately held, clinical-stage biopharmaceutical company bringing transformational treatments to people living with cardiometabolic disease.

The company’s lead asset, bimagrumab, is being advanced in a Phase 2b study as a novel treatment for obesity to help adults achieve and maintain both substantial fat loss and a healthy body composition, with additional indications to follow. Versanis was founded in 2021 and is a portfolio company of Aditum Bio, Atlas Venture and Medicxi.